PBAC's latest decision on Risedronate sodium: Deferred (2023). Considered for Primary prevention of fractures in patients with osteoporosis aged less than 70 years with a BMD T-score of -2.5 or less, without a history of minimal trauma fracture.
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
—
ICER not stated
Submissions
6
first 2006
Submissions
6
2006 → 2023
Eligible population
Patients aged less than 70 years with osteoporosis (BMD T-score of -2.5 or less) without a history of minimal trauma fracture
placebo or 'watchful waiting' (patient monitoring and standard management with calcium and vitamin D)
Economic model
CEA
ICER note
Document appears truncated; economic model details not fully available in provided text.
ICER (historical)
$15k/QALY–$45k/QALY across 2 submissions (2006–2008) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2006: Not recommended · Authority required — ICER $45k/QALY
Mar 2007: Recommended with restriction · Authority Required